ABSTRACT
Background Women with HCM present at a more advanced stage of the disease and have a higher risk of heart failure and death. The factors contributing to these differences are unclear. We aimed to investigate sex differences in clinical and genetic factors associated with adverse outcomes in the Sarcomeric Human Cardiomyopathy Registry (SHaRe).
Methods Cox proportional hazard models were fit with a sex interaction term to determine if significant sex differences existed in the association between risk factors and outcomes. Models were fit separately for women and men to find the sex-specific hazard ratio.
Results After a mean follow-up of 6.4 years, women had a higher risk of heart failure (HR 1.51; 95% CI 1.21-1.88, p=0.0003) but a lower risk of atrial fibrillation (0.74; 0.59-0.93; p<0.0001) and ventricular arrhythmia (0.60; 0.38-0.94; p=0.027) than men. No sex difference was observed for death (p=0.84). Sarcomere-positive men had a higher risk of heart failure and death, not seen in women (p-heterogeneity=0.006 & p-heterogeneity=0.035, respectively). MYBPC3 variants were associated with lower heart failure risk in women than other HCM subgroups, with no significant change for men (p-heterogeneity <0.0001). Women with moderate risk of ventricular arrhythmia (4% to <6% ESC risk score) were at a higher risk of ventricular arrhythmia than those scoring <4%, not observed in men (p-heterogeneity= 0.019).
Conclusion Clinical and genetic factors contributing to adverse outcomes in HCM affect women and men differently. Research to inform sex-specific management of HCM could improve outcomes for both sexes.
Competing Interest Statement
JI receives research grant support from Bristol Myers Squibb. JWR consultant for Bayer, Merk, Bristol Myers Squibb, Cytokinetics. CA has received honoraria from Astra Zeneca and Amgen. NL is a consultant for Bristol Myers Squibb, Cytokinetics, Pfizer, Tenaya and Sarepta and receives grant support from Pfizer. CYH is a consultant for Bristol Myers Squibb, Cytokinetics, and Viz-AI and receives research support from Bristol Myers Squibb, Cytokinetics, and Pfizer. All remaining authors have nothing to disclose.
Funding Statement
The Sarcomeric Human Cardiomyopathy Registry (SHaRe) is supported by unrestricted research grants from Bristol Myers Squibb, Pfizer, inc, and Cytokinetics, including funds to individual sites for database support. No sponsor played a role in the design or conduct of this study nor participated in the articles preparation, review, or approval. JI is the recipient of a National Health and Medical Research Council (NHMRC) Career Development Fellowship (#1162929). CS is the recipient of a National Health and Medical Research Council (NHMRC) Practitioner Fellowship (#1154992) and a New South Wales Health Cardiovascular Disease Clinical Scientist Grant. This study was partly funded by a New South Wales (NSW) Health Cardiovascular Research Capacity Program early-mid career research grant.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval requiring participant informed consent was granted by Cincinnati Children's Hospital, United States of America (USA); Children's Hospital of Philadelphia, USA; Michigan Medical, USA; Yale Medical, USA; Royal Brompton Hospital, United Kingdom; Erasmus University Medical Center, The Netherlands; Florence Centre for Cardiomyopathies, Italy; and Sydney Local Health District, Royal Prince Alfred Hospital, Australia; InCor, Heart Institute, University of Sao Paulo, Brazil institutional review boards. Ethical approval with a waiver of consent was granted by Stanford School of Medicine, USA; Brigham and Women's Hospital, USA; Boston Children's Hospital, USA; Pennsylvania University Medical Center, USA; and Sydney Local Health District, Royal Prince Alfred Hospital, Australia institutional review boards.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors and according to ethical approvals
ABBREVIATIONS
- HCM
- Hypertrophic cardiomyopathy
- SHaRe
- Sarcomeric Human Cardiomyopathy Registry
- AF
- Atrial fibrillation
- ICD
- Implantable cardioverter defibrillator
- LV
- Left ventricular
- P/LP
- Pathogenic/Likely pathogenic
- VUS
- Variant of unknown significance
- NYHA
- New York Heart Association
- LVOTO
- Left ventricular outflow tract obstruction
- LA
- Left atrial
